Osteoporosis: Seven-Market Drug Forecast and Market Analysis

Osteoporosis: Seven-Market Drug Forecast and Market Analysis

Summary

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Osteoporosis market through 2033.

Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue, predisposing a person to bone fragility and susceptibility to fracture. Common sites of fracture include the spine, hip, distal forearm, and proximal humerus. Such fractures are a major cause of morbidity in the general population and a patient’s recovery can be slow, with many requiring full-time care.

Major drivers of growth in the osteoporosis market during the forecast period include the following -

• The increased use of Evenity across the 7MM, which will be accelerated by growing physician familiarity and clinical experience following recent launch
• The rising use of anabolic therapies, which are typically more expensive than anti-resorptive agents, in particular low-cost bisphosphonates
• An increase in the number of people with osteoporosis, in line with the growth of the global aging population

Major barriers to growth in the osteoporosis market during the forecast period will include the following -

• High cost of anabolic therapies and dual-action Evenity compared to affordable bisphosphonates, which have established long-term safety and efficacy profiles
• Loss of patent protection and/or market exclusivity for some products during the forecast period, and the subsequent launches of biosimilars and generics; this includes the expected launch of denosumab biosimilars in 2025 and 2027 across the 7MM, which will take substantial market share from marketed Prolia/Pralia
• Low patient compliance with many osteoporosis therapies due to adverse side effects, frequent administration leading to lifestyle disruption, the discomfort of regular subcutaneous or intravenous injections, as well as patients missing treatment appointments, especially due to other medical complications in older patients

Scope

• Overview of osteoporosis, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized osteoporosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the osteoporosis therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for osteoporosis treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global osteoporosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM osteoporosis therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM osteoporosis therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Please note:this is delivered as a Zip file.